GET DAILY SIGNALSGenmab (GMAB) Q3 Revenue Climbs 16% as Profits Beat Estimates
Key Takeaways
- Third-quarter revenue rose 16% year over year to $1,187 million, essentially in line with the roughly $1,200 million consensus estimate.
- Operating profit of $431 million beat expectations by about 22%, while net income of $342 million came in well above the consensus of roughly $219 million.
- Royalty revenue climbed to $991 million, powered by 19% growth in DARZALEX and continued strength from Kesimpta.
- Global net sales of EPKINLY/TEPKINLY jumped 47% to $491 million in the first nine months of 2026.
- Genmab maintained its full-year 2026 guidance and now expects revenue to land toward the upper end of its $4,325–$4,525 million range.
- Three positive Phase 3 readouts announced after quarter-end support potential regulatory submissions and launches in 2027.
Earnings Context and Why It Matters
Genmab’s third-quarter report stands out for investors because the Danish biotechnology company is shifting from a royalty-heavy model toward a broader oncology franchise. Royalties from established products like DARZALEX and Kesimpta continue to support the top line, yet growth is increasingly driven by Genmab’s own marketed therapy EPKINLY and its advancing late-stage pipeline. The quarter also reflects the integration of Merus, which brought some acquisition-related costs. With several key data readouts now in hand, the results provide a clearer picture of whether GMAB can turn pipeline momentum into more diversified, sustained revenue growth.
Reported Results
Genmab reported third-quarter 2026 revenue of $1,187 million, up 16.1% from $1,022 million in the prior-year period and slightly below the Bloomberg consensus of $1,200 million. Royalty revenue reached $991 million, compared with $841 million a year earlier, driven primarily by higher net sales of DARZALEX and Kesimpta. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Operating profit came in at $431 million, exceeding the consensus estimate of roughly $352 million by about 22%, though it was down from $459 million in the same quarter last year. Net income was $342 million, a decline from $401 million a year ago but significantly ahead of the roughly $219 million analysts had anticipated. Basic earnings per share (EPS) were $5.58, down from $6.51 in the prior-year quarter, while diluted EPS were $5.51 versus $6.46.
For the first nine months of 2026, revenue rose 22% to $3,238 million, while operating profit dipped to $986 million from $1,007 million a year earlier. Genmab reiterated its full-year 2026 guidance, targeting revenue of $4,325–$4,525 million and adjusted operating profit of $1,065–$1,385 million, with management indicating revenue is expected to finish in the upper part of that range.
Market Reaction and Investor Sentiment
Genmab’s American depositary receipts (ADRs) slipped roughly 2% on the day despite the operating-profit and net-income beats. The muted reaction likely reflects revenue arriving slightly below consensus, alongside a sharp rise in operating expenses as the company invests heavily in its pipeline and launch-readiness efforts. Net income also fell year over year, pressured by higher research and development costs and acquisition-related charges tied to the Merus integration. Still, investors appeared to focus on the positive Phase 3 readouts for epcoritamab, Rina-S, and petosemtamab, which reinforce the company’s longer-term growth narrative.
Forward Outlook and Key Factors to Monitor
Following this report, the primary story centers on Genmab’s late-stage pipeline. After quarter-end, the company announced positive Phase 3 results across three assets: epcoritamab in frontline diffuse large B-cell lymphoma (DLBCL), Rina-S in platinum-resistant ovarian cancer, and petosemtamab in first-line head and neck cancer. Management said these results support multiple regulatory submissions and potential product launches in 2027.
Investors should watch how quickly Genmab advances these regulatory discussions and whether the data translate into approvals. The company reiterated ambitious peak-sales targets of more than $3 billion for EPKINLY, more than $2 billion for Rina-S, and a multibillion-dollar opportunity for petosemtamab, including $1 billion in petosemtamab sales by 2029.
Cost discipline will also matter. Genmab expects fourth-quarter operating expenses to rise significantly as it scales manufacturing, clinical development, and launch preparation. Finally, the eventual expiration of DARZALEX royalties remains a long-term consideration, making the successful commercialization of Genmab’s own products a key focus for the years ahead.
Using Tickeron’s Tools for Biotech Research
In my own work I often rely on Tickeron’s AI Screener to quickly compare names like GMAB against peers on fundamentals and technical signals. The platform’s customizable filters help surface comparable opportunities without hours of manual work. I find it especially useful when evaluating how a stock’s pipeline progress stacks up against industry trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GMAB in -4.63% downward trend, falling for three consecutive days on October 08, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where GMAB declined for three days, in 208 of 293 cases, the price declined further within the following month. The odds of a continued downward trend are 71%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
GMAB broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GMAB just turned positive on October 19, 2026. Looking at past instances where GMAB's MACD turned positive, the stock continued to rise in 26 of 43 cases over the following month. The odds of a continued upward trend are 60%.
Following a +11.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMAB advanced for three days, in 197 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 147 of 213 cases where GMAB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. GMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.444) is normal, around the industry mean (2.904). P/E Ratio (41.171) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (4.454) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (5.192) is also within normal values, averaging (440.869).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an international biotechnology company, which develops human antibody therapeutics for the treatment of cancer and other diseases.
Industry Biotechnology
Advertisement